SR9009 | Stenabolic | CAS#1379686-30-2 | Rev-ErbA Agonist

MedKoo Cat#: 532783 | Name: SR9009

Description:

WARNING: This product is for research use only, not for human or veterinary use.

SR9009 is a rev-ErbA agonist. It increases the constitutive repression of genes regulated by Rev-ErbA with a half-maximum inhibitory concentration (IC50) = 670 nM for Rev-ErbAα and IC50 = 800 nM for Rev-ErbAβ.

Chemical Structure

SR9009

CAS#1379686-30-2

Theoretical Analysis

MedKoo Cat#: 532783

Name: SR9009

CAS#: 1379686-30-2

Chemical Formula: C20H24ClN3O4S

Exact Mass: 437.1176

Molecular Weight: 437.94

Elemental Analysis: C, 54.85; H, 5.52; Cl, 8.09; N, 9.60; O, 14.61; S, 7.32

Price and Availability

Size	Price	Availability
25mg	USD 90.00	Ready to ship
50mg	USD 150.00	Ready to ship
100mg	USD 250.00	Ready to ship
200mg	USD 450.00	Ready to ship
500mg	USD 950.00	Ready to ship
1g	USD 1,650.00	Ready to ship
2g	USD 2,950.00	Ready to ship

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

SR9009; SR 9009; SR-9009; Stenabolic.

IUPAC/Chemical Name

ethyl 3-[[(4-chlorophenyl)methyl-[(5-nitrothiophen-2-yl)methyl]amino]methyl]pyrrolidine-1-carboxylate

InChi Key

MMJJNHOIVCGAAP-UHFFFAOYSA-N

InChi Code

InChI=1S/C20H24ClN3O4S/c1-2-28-20(25)23-10-9-16(13-23)12-22(11-15-3-5-17(21)6-4-15)14-18-7-8-19(29-18)24(26)27/h3-8,16H,2,9-14H2,1H3

SMILES Code

O=C(N1CC(CN(CC2=CC=C(Cl)C=C2)CC3=CC=C([N+]([O-])=O)S3)CC1)OCC

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO and ethanol

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Certificate of Analysis

View CoA: current batch, Lot#C21R04B14

QC Data

View QC data: current batch, Lot#C21R04B14

Safety Data Sheet (SDS)

View Safety Data Sheet (SDS)

Instruction

View handling instruction

Biological target:

SR9009 is a REV-ERBα/β agonist with IC50s of 670 nM and 800 nM for REV-ERBα and REV-ERBβ, respectively.

In vitro activity:

SR9009 could inhibit GRP78-induced autophagy and de novo lipogenesis processes and had a synergistic effect with proteasome inhibitors in multiple myeloma (MM) models. SR9009 decreased MM viability, proliferation rate and induced an apoptotic response in a dose-dependent manner. Reference: World J Oncol. 2023 Dec;14(6):464-475. https://pubmed.ncbi.nlm.nih.gov/38022411/

In vivo activity:

Weight loss of SR9009-treated animals was 60% greater than vehicle treatments. SR9009 treated mice exhibited a more severe reduction in adiposity. Plasma non-esterified fatty acids were reduced (23%) along with plasma glucose (19%) in the SR9009 treated animals. In the white adipose tissue, SR9009 treatment resulted in a decrease in expression of genes encoding enzymes involved in triglyceride (TG) synthesis as is also observed in lean mice. Reference: Nature. 2012 Mar 29;485(7396):62-8. https://pubmed.ncbi.nlm.nih.gov/22460951/

	Solvent	mg/mL	mM
Solubility
	DMSO	87.0	198.66
	Ethanol	87.0	198.66

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 437.94 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Wang R, Liu SL, Guo QQ, Shi XH, Ma MM. Circadian Clock REV-ERBs Agonist SR9009 Induces Synergistic Antitumor Activity in Multiple Myeloma by Suppressing Glucose-Regulated Protein 78-Dependent Autophagy and Lipogenesis. World J Oncol. 2023 Dec;14(6):464-475. doi: 10.14740/wjon1681. Epub 2023 Oct 21. PMID: 38022411; PMCID: PMC10681778. 2. Shen W, Zhang W, Ye W, Wang H, Zhang Q, Shen J, Hong Q, Li X, Wen G, Wei T, Zhang J. SR9009 induces a REV-ERB dependent anti-small-cell lung cancer effect through inhibition of autophagy. Theranostics. 2020 Mar 15;10(10):4466-4480. doi: 10.7150/thno.42478. PMID: 32292508; PMCID: PMC7150483. 3. Solt LA, Wang Y, Banerjee S, Hughes T, Kojetin DJ, Lundasen T, Shin Y, Liu J, Cameron MD, Noel R, Yoo SH, Takahashi JS, Butler AA, Kamenecka TM, Burris TP. Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists. Nature. 2012 Mar 29;485(7396):62-8. doi: 10.1038/nature11030. PMID: 22460951; PMCID: PMC3343186. 4. Reitz CJ, Alibhai FJ, Khatua TN, Rasouli M, Bridle BW, Burris TP, Martino TA. SR9009 administered for one day after myocardial ischemia-reperfusion prevents heart failure in mice by targeting the cardiac inflammasome. Commun Biol. 2019 Oct 3;2:353. doi: 10.1038/s42003-019-0595-z. PMID: 31602405; PMCID: PMC6776554.

In vitro protocol:

In vivo protocol:

1. Solt LA, Wang Y, Banerjee S, Hughes T, Kojetin DJ, Lundasen T, Shin Y, Liu J, Cameron MD, Noel R, Yoo SH, Takahashi JS, Butler AA, Kamenecka TM, Burris TP. Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists. Nature. 2012 Mar 29;485(7396):62-8. doi: 10.1038/nature11030. PMID: 22460951; PMCID: PMC3343186. 2. Reitz CJ, Alibhai FJ, Khatua TN, Rasouli M, Bridle BW, Burris TP, Martino TA. SR9009 administered for one day after myocardial ischemia-reperfusion prevents heart failure in mice by targeting the cardiac inflammasome. Commun Biol. 2019 Oct 3;2:353. doi: 10.1038/s42003-019-0595-z. PMID: 31602405; PMCID: PMC6776554.

1: Darmanto AG, Jan JS, Yen TL, Huang SW, Teng RD, Wang JY, Taliyan R, Sheu JR, Yang CH. Targeting Circadian Protein Rev-erbα to Alleviate Inflammation, Oxidative Stress, and Enhance Functional Recovery Following Brain Trauma. Antioxidants (Basel). 2024 Jul 25;13(8):901. doi: 10.3390/antiox13080901. PMID: 39199147; PMCID: PMC11351136. 2: Li X, Zhuang R, Lu Z, Wu F, Wu X, Zhang K, Wang M, Li W, Zhang H, Zhu W, Zhang B. Nobiletin promotes lipolysis of white adipose tissue in a circadian clock-dependent manner. J Nutr Biochem. 2024 Oct;132:109696. doi: 10.1016/j.jnutbio.2024.109696. Epub 2024 Aug 1. PMID: 39094217. 3: Li L, Yang C, Qiao X, Yang X, Zhang J, Cui M, Li Z, Tian A, Li X, Zou X, Li Y, He W, Chen Y, He X. Regulation of exercise ability and glycolipid metabolism by synthetic SR9009 analogues as new REV-ERB-α agonists. Bioorg Med Chem. 2024 Sep 1;111:117845. doi: 10.1016/j.bmc.2024.117845. Epub 2024 Jul 20. PMID: 39059249. 4: Teppan J, Schwanzer J, Rittchen S, Bärnthaler T, Lindemann J, Nayak B, Reiter B, Luschnig P, Farzi A, Heinemann A, Sturm E. The disrupted molecular circadian clock of monocytes and macrophages in allergic inflammation. Front Immunol. 2024 May 28;15:1408772. doi: 10.3389/fimmu.2024.1408772. PMID: 38863703; PMCID: PMC11165079. 5: Kwak YB, Yoon J, Yoo HH. Rapid investigating of phase I metabolites of SR9009 in vitro horse liver microsomes via feature-based molecular networking approach: Potential applications in doping control. J Pharm Biomed Anal. 2024 Aug 15;246:116190. doi: 10.1016/j.jpba.2024.116190. Epub 2024 Apr 30. PMID: 38735208. 6: Huang ZN, Wang J, Wang ZY, Min LY, Ni HL, Han YL, Tian YY, Cui YZ, Han JX, Cheng XF. SR9009 attenuates inflammation-related NPMSC pyroptosis and IVDD through NR1D1/NLRP3/IL-1β pathway. iScience. 2024 Apr 16;27(5):109733. doi: 10.1016/j.isci.2024.109733. PMID: 38689641; PMCID: PMC11059531. 7: Sun L, Huang K, Deng Q, Zhu Y, Cao Y, Dong K, Yang S, Li Y, Wu S, Huang R. REV-ERBα negatively regulates NLRP6 transcription and reduces the severity of Salmonella infection in mice. Heliyon. 2024 Apr 4;10(8):e28432. doi: 10.1016/j.heliyon.2024.e28432. PMID: 38628724; PMCID: PMC11019167. 8: Song W, Ye L, Tang Q, Lu X, Huang X, Xie M, Yu S, Yuan Z, Chen L. Rev-erbα attenuates refractory periapical periodontitis via M1 polarization: An in vitro and in vivo study. Int Endod J. 2024 Apr;57(4):451-463. doi: 10.1111/iej.14024. Epub 2024 Jan 27. PMID: 38279698. 9: Hashizume H, Motonari H, Yamamoto K, Nakamura Y, Hisaoka-Nakashima K, Morioka N. Stimulation of nuclear receptor REV-ERBs alleviates monosodium iodoacetate- induced osteoarthritis pathology of mice and the induction of inflammatory molecules expression in primary cultured chondrocytes. Int Immunopharmacol. 2024 Jan 25;127:111349. doi: 10.1016/j.intimp.2023.111349. Epub 2023 Dec 11. PMID: 38086272. 10: Wang R, Liu SL, Guo QQ, Shi XH, Ma MM. Circadian Clock REV-ERBs Agonist SR9009 Induces Synergistic Antitumor Activity in Multiple Myeloma by Suppressing Glucose-Regulated Protein 78-Dependent Autophagy and Lipogenesis. World J Oncol. 2023 Dec;14(6):464-475. doi: 10.14740/wjon1681. Epub 2023 Oct 21. PMID: 38022411; PMCID: PMC10681778. 11: Chu SJ, Liao WI, Pao HP, Wu SY, Tang SE. Targeting Rev-Erbα to protect against ischemia-reperfusion-induced acute lung injury in rats. Respir Res. 2023 Oct 12;24(1):247. doi: 10.1186/s12931-023-02547-7. PMID: 37828537; PMCID: PMC10571317. 12: Chen Y, Li J, Li S, Cheng Y, Fu X, Li J, Zhu L. Uncovering the Novel Role of NR1D1 in Regulating BNIP3-Mediated Mitophagy in Ulcerative Colitis. Int J Mol Sci. 2023 Sep 18;24(18):14222. doi: 10.3390/ijms241814222. PMID: 37762536; PMCID: PMC10531686. 13: Li C, Yang D, Yang W, Wang Y, Li D, Li Y, Xiao B, Zhang H, Zhao H, Dong H, Zhang J, Chu G, Wang A, Jin Y, Liu Y, Chen H. Hypoxia activation attenuates progesterone synthesis in goat trophoblast cells via NR1D1 inhibition of StAR expression†. Biol Reprod. 2023 Nov 15;109(5):720-735. doi: 10.1093/biolre/ioad094. PMID: 37552055. 14: Ka NL, Park MK, Kim SS, Jeon Y, Hwang S, Kim SM, Lim GY, Lee H, Lee MO. NR1D1 Stimulates Antitumor Immune Responses in Breast Cancer by Activating cGAS- STING Signaling. Cancer Res. 2023 Sep 15;83(18):3045-3058. doi: 10.1158/0008-5472.CAN-23-0329. PMID: 37395684; PMCID: PMC10538367. 15: Saiz N, Herrera-Castillo L, Gómez-Boronat M, Delgado MJ, Isorna E, de Pedro N. Daily rhythms of REV-ERBα and its role as transcriptional repressor of clock genes in fish hepatic oscillator. Comp Biochem Physiol A Mol Integr Physiol. 2023 Sep;283:111458. doi: 10.1016/j.cbpa.2023.111458. Epub 2023 Jun 7. PMID: 37290737. 16: Prasad C, Hahn K, Duraisamy SK, Salathe MA, Huang SK, Burris TP, Sundar IK. Rev-erbα agonists suppresses TGFβ1-induced fibroblast-to-myofibroblast transition and pro-fibrotic phenotype in human lung fibroblasts. Biochem Biophys Res Commun. 2023 Aug 20;669:120-127. doi: 10.1016/j.bbrc.2023.05.092. Epub 2023 May 24. PMID: 37269594; PMCID: PMC11034855. 17: Yang Y, Bai Y, Wang X, Guo Y, Yu Z, Feng D, Zhang F, Li D, Han P. Clock gene NR1D1 might be a novel target for the treatment of bladder cancer. Urol Oncol. 2023 Jul;41(7):327.e9-327.e18. doi: 10.1016/j.urolonc.2023.04.021. Epub 2023 May 18. PMID: 37208228. 18: Ni Y, Nan S, Zheng L, Zhang L, Zhao Y, Fu Z. Time-dependent effect of REV- ERBα agonist SR9009 on nonalcoholic steatohepatitis and gut microbiota in mice. Chronobiol Int. 2023 Jun 3;40(6):769-782. doi: 10.1080/07420528.2023.2207649. Epub 2023 May 10. PMID: 37161366. 19: Makhija S, Griffett JD, Veerakanellore GB, Burris TP, Elgendy B, Griffett K. REV-ERB activation as a novel pharmacological approach for treating inflammatory pain. Front Pharmacol. 2023 Apr 19;14:1171931. doi: 10.3389/fphar.2023.1171931. PMID: 37153791; PMCID: PMC10154555. 20: Sheng M, Chen X, Yu Y, Wu Q, Kou J, Chen G. Rev-erbα agonist SR9009 protects against cerebral ischemic injury through mechanisms involving Nrf2 pathway. Front Pharmacol. 2023 Mar 31;14:1102567. doi: 10.3389/fphar.2023.1102567. PMID: 37063298; PMCID: PMC10102520.